) reported positive results of the OpT2mise trial, validating the
efficacy of the MiniMed insulin pump in achieving better glucose
control. The study results were published online in the July 3,
2014 issue of the medical journal, The Lancet.
Per the study, Medtronic's MiniMed insulin pumps are more
effective in lowering the glucose level in insulin-administered
type 2 diabetes patients, compared with multiple daily injections
The OpT2mise Trial
Hyperglycemia or type 2 diabetes refers to the medical condition
in which high levels of glucose exist in a patient's blood. In such
situations, one's body cells do not get the required insulin from
the body and thus need to be dosed with insulin artificially from
The purpose of the randomized controlled OpT2mise trail was to
prove the comparative effectiveness of insulin pump treatment
versus MDIs in controlling the glucose level of a insulin-receiving
type 2 diabetes patient.
This global study, funded by Medtronic, enrolled 331 type 2
diabetes patients who complained of poor glycemic control despite
being treated with MDIs. The age group of the trial patients ranged
between 30 and 75 years. These patients with insulin analogues were
enrolled into a 2-month dose-optimization run-in period.
This multi center trial was conducted at 36 hospitals, tertiary
care centers, and referral centers in Canada, Europe, Israel, South
Africa, and the U.S. Notably, it is the largest global study to
have estimated the comparative efficacy of insulin pump therapy
over MDIs in type 2 diabetes people with poor glycemic control.
Results of the Study
In the OpT2mise trial, type 2 diabetes patients using insulin
pumps achieved a mean A1C (average blood glucose) reduction of 1.1%
compared to only a 0.4 % reduction in those using MDIs. It is
noteworthy to mention that this improvement in glucose control was
achieved without any episodes of severe hypoglycemia (incidence of
abnormally low glucose level in the blood).
Moreover, the daily dose of insulin was 20.4% lower for patients
administered with insulin pump therapy compared to those who were
provided injection therapy. In addition, no difference in weight
gain was observed between the two sets of patients.
Approximately 20 million people around the world with type 2
diabetes require insulin replacement therapy. However, many of them
still fail to achieve glycemic control despite being administered
insulin via MDIs. For such patients, insulin pump therapy should
prove to be a life-saving boon that can safely reduce A1C without
causing hypoglycemic episodes.
Currently, Medtronic carries a Zacks Rank #3 (Hold). Some
better-ranked medical product stocks that warrant a look are
Wright Medical Group Inc.
ICU Medical, Inc.
Nxstage Medical, Inc.
). While Wright Medical sports a Zacks Rank #1 (Strong Buy),
Nxstage Medical and ICU Medical bear a Zacks Rank #2
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
WRIGHT MEDICAL (WMGI): Free Stock Analysis
NXSTAGE MEDICAL (NXTM): Free Stock Analysis
ICU MEDICAL INC (ICUI): Free Stock Analysis
To read this article on Zacks.com click here.